Form 4: Labcorp Executive Granted Stock Options, RSUs

Labcorp Holdings Inc. EVP, CIO & CTO Akinbolade Oyegunwa received 2,400 non-qualified stock options and 810 restricted stock units on February 10, 2026.

Summary

• Akinbolade Oyegunwa, Executive Vice President, Chief Information Officer, and Chief Technology Officer of Labcorp Holdings Inc. (LH), was granted equity compensation.
• On February 10, 2026, Oyegunwa acquired 2,400 non-qualified stock options with an exercise price of $284.50 per share.
• These stock options vest in three equal annual installments, beginning on February 10, 2027, and expire on February 9, 2036.
• Additionally, Oyegunwa acquired 810 Restricted Stock Units (RSUs) on February 10, 2026.
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The RSUs also vest in three equal annual installments, beginning on February 10, 2027.
• Following these transactions, Oyegunwa directly beneficially owns 2,400 non-qualified stock options and an aggregate of 2,420 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine event. While it doesn't signal new operational performance, it reflects standard corporate governance practices aimed at aligning executive and shareholder interests.

Positives

• The grant of stock options and restricted stock units aligns the executive's financial interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key executives in publicly traded companies.

Industry Context

StockSavvy.ai notes that the granting of equity compensation, such as stock options and restricted stock units, to senior executives is a common and widely accepted practice across the healthcare and diagnostics industry. This strategy is typically employed to align management incentives with shareholder value creation and to ensure executive retention.

Comparison to Industry Standards

• Equity compensation packages, including stock options and RSUs, are standard components of executive remuneration across major U.S. public companies, including peers in the healthcare sector like Quest Diagnostics (DGX) and other large diagnostic service providers.
• The vesting schedule of three equal annual installments is a common structure designed to encourage long-term commitment and performance, similar to practices observed at companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR).

Stakeholder Impact

• Shareholders: The equity grants are intended to align the executive's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: No direct impact on general employees is indicated by this specific filing, though executive compensation practices can influence overall company culture and morale.

Next Steps

• The stock options and Restricted Stock Units will vest in three equal annual installments, beginning on February 10, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not contain new material information that would alter the fundamental investment thesis for Labcorp Holdings Inc. Investors should 'hold' their position, as this transaction is an expected part of executive remuneration and does not indicate a change in company outlook or performance.

Keywords

Labcorp, LH, stock options, restricted stock units, RSU, executive compensation, insider transaction, Form 4, corporate governance